NASDAQ:PRNB - Principia Biopharma Stock Price, Forecast & News

Principia Biopharma trades on the NASDAQ under the ticker symbol "PRNB."

Principia Biopharma Inc (NASDAQ:PRNB) announced its earnings results on Tuesday, November, 5th. The company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by $0.08. Principia Biopharma had a net margin of 11.88% and a negative return on equity of 11.95%. View Principia Biopharma's Earnings History.

Principia Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Principia Biopharma.

3 equities research analysts have issued 12-month price targets for Principia Biopharma's stock. Their forecasts range from $42.00 to $57.00. On average, they expect Principia Biopharma's share price to reach $50.00 in the next year. This suggests a possible upside of 2.0% from the stock's current price. View Analyst Price Targets for Principia Biopharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Principia Biopharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Principia Biopharma.

News headlines about PRNB stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Principia Biopharma earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Principia Biopharma.

Principia Biopharma saw a increase in short interest during the month of November. As of November 29th, there was short interest totalling 508,000 shares, an increase of 5.1% from the November 14th total of 483,500 shares. Based on an average trading volume of 261,800 shares, the days-to-cover ratio is presently 1.9 days. Currently, 2.3% of the company's shares are short sold. View Principia Biopharma's Current Options Chain.

Some companies that are related to Principia Biopharma include BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Ascendis Pharma A/S (ASND), Mirati Therapeutics (MRTX), FibroGen (FGEN), United Therapeutics (UTHR), Intercept Pharmaceuticals (ICPT), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), Blueprint Medicines (BPMC), Evotec (EVTCY), Alkermes (ALKS), SAGE Therapeutics (SAGE), Myokardia (MYOK) and Genmab A/S (GMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Principia Biopharma investors own include Momo (MOMO), Baidu (BIDU), Krystal Biotech (KRYS), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM), Corbus Pharmaceuticals (CRBP) and Eyegate Pharmaceuticals (EYEG).

(PRNB) raised $75 million in an IPO on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Principia Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Redmile Group LLC (2.41%), Pictet Asset Management Ltd. (0.85%), Massachusetts Financial Services Co. MA (1.11%), State Street Corp (0.76%), Alps Advisors Inc. (0.20%) and Point72 Asset Management L.P. (0.13%). Company insiders that own Principia Biopharma stock include Daniel J Becker, David Goldstein, Leaf Ventures Ii LP New, Orbimed Advisors Llc, Plc Glaxosmithkline, Simeon George and Srinivas Akkaraju. View Institutional Ownership Trends for Principia Biopharma.

PRNB stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Squarepoint Ops LLC, Alps Advisors Inc. and Massachusetts Financial Services Co. MA. Company insiders that have sold Principia Biopharma company stock in the last year include David Goldstein, Leaf Ventures Ii LP New and Orbimed Advisors Llc. View Insider Buying and Selling for Principia Biopharma.

PRNB stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, Pictet Asset Management Ltd., Strs Ohio, Russell Investments Group Ltd., State Street Corp and Metropolitan Life Insurance Co NY. Company insiders that have bought Principia Biopharma stock in the last two years include Daniel J Becker, Leaf Ventures Ii LP New, Plc Glaxosmithkline, Simeon George and Srinivas Akkaraju. View Insider Buying and Selling for Principia Biopharma.

Shares of PRNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PRNB stock can currently be purchased for approximately $49.02.

Principia Biopharma has a market capitalization of $1.61 billion and generates $69.14 million in revenue each year. The company earns $18.17 million in net income (profit) each year or $0.57 on an earnings per share basis. Principia Biopharma employs 65 workers across the globe.View Additional Information About Principia Biopharma.

The official website for Principia Biopharma is http://www.principiabio.com/.

Principia Biopharma's mailing address is 220 East Grand Avenue, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-416-7700 or via email at [email protected]